These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 32860123)

  • 21. Cardioprotective effect of renin-angiotensin inhibitors and β-blockers in trastuzumab-related cardiotoxicity.
    Ohtani K; Ide T; Hiasa KI; Sakamoto I; Yamashita N; Kubo M; Tsutsui H
    Clin Res Cardiol; 2019 Oct; 108(10):1128-1139. PubMed ID: 30859381
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Time Trends of Left Ventricular Ejection Fraction and Myocardial Deformation Indices in a Cohort of Women with Breast Cancer Treated with Anthracyclines, Taxanes, and Trastuzumab.
    Tan TC; Bouras S; Sawaya H; Sebag IA; Cohen V; Picard MH; Passeri J; Kuter I; Scherrer-Crosbie M
    J Am Soc Echocardiogr; 2015 May; 28(5):509-14. PubMed ID: 25772019
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exercise as a diagnostic and therapeutic tool for the prevention of cardiovascular dysfunction in breast cancer patients.
    Howden EJ; Bigaran A; Beaudry R; Fraser S; Selig S; Foulkes S; Antill Y; Nightingale S; Loi S; Haykowsky MJ; La Gerche A
    Eur J Prev Cardiol; 2019 Feb; 26(3):305-315. PubMed ID: 30376366
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Longitudinal assessment of concurrent changes in left ventricular ejection fraction and left ventricular myocardial tissue characteristics after administration of cardiotoxic chemotherapies using T1-weighted and T2-weighted cardiovascular magnetic resonance.
    Jordan JH; D'Agostino RB; Hamilton CA; Vasu S; Hall ME; Kitzman DW; Thohan V; Lawrence JA; Ellis LR; Lash TL; Hundley WG
    Circ Cardiovasc Imaging; 2014 Nov; 7(6):872-9. PubMed ID: 25273568
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Left ventricular end-diastolic volume as early indicator of trastuzumab-related cardiotoxicity in HER2+ breast cancer patients: results from a single-center retrospective study.
    Bergamini C; Torelli F; Ghiselli L; Rossi A; Trevisani L; Vinco G; Truong S; Benfari G; LA Russa F; Golia G; Molino A; Vassanelli C
    Minerva Cardioangiol; 2017 Jun; 65(3):278-287. PubMed ID: 27886160
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Late characterisation of cardiac effects following anthracycline and trastuzumab treatment in breast cancer patients.
    Kimball A; Patil S; Koczwara B; Raman KS; Perry R; Grover S; Selvanayagam J
    Int J Cardiol; 2018 Jun; 261():159-161. PubMed ID: 29576422
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Timing of the negative effects of trastuzumab on cardiac mechanics after anthracycline chemotherapy.
    Cadeddu C; Piras A; Dessì M; Madeddu C; Mantovani G; Scartozzi M; Hagendorff A; Colonna P; Mercuro G
    Int J Cardiovasc Imaging; 2017 Feb; 33(2):197-207. PubMed ID: 27696298
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Prospective Cohort Study on Cardiotoxicity of Adjuvant Trastuzumab Therapy in Breast Cancer Patients.
    Matos E; Jug B; Blagus R; Zakotnik B
    Arq Bras Cardiol; 2016 Jul; 107(1):40-7. PubMed ID: 27305108
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prolonged electromechanical delay as an early predictor of trastuzumab-induced cardiotoxicity in patients undergoing treatment for breast cancer.
    Choe JC; Choi JH; Choi JH; Ahn J; Park JS; Lee HW; Oh JH; Lee HC; Cha KS; Hong TJ
    Clin Cardiol; 2018 Oct; 41(10):1308-1314. PubMed ID: 30239009
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of mitral annular velocity as an alternative marker of left ventricular global longitudinal strain to detect the risk of cancer therapy-related cardiac disorders.
    Ichikawa N; Nishizaki Y; Miyazaki S; Nojima M; Kataoka K; Kasahara R; Takei J; Asano T; Komiyama N
    Echocardiography; 2024 Jul; 41(7):e15877. PubMed ID: 38952246
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnostic and Prognostic Value of Myocardial Work Indices for Identification of Cancer Therapy-Related Cardiotoxicity.
    Calvillo-Argüelles O; Thampinathan B; Somerset E; Shalmon T; Amir E; Steve Fan CP; Moon S; Abdel-Qadir H; Thevakumaran Y; Day J; Woo A; Wintersperger BJ; Marwick TH; Thavendiranathan P
    JACC Cardiovasc Imaging; 2022 Aug; 15(8):1361-1376. PubMed ID: 35926895
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients.
    Sawaya H; Sebag IA; Plana JC; Januzzi JL; Ky B; Cohen V; Gosavi S; Carver JR; Wiegers SE; Martin RP; Picard MH; Gerszten RE; Halpern EF; Passeri J; Kuter I; Scherrer-Crosbie M
    Am J Cardiol; 2011 May; 107(9):1375-80. PubMed ID: 21371685
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of increase in heart rate after anthracycline chemotherapy on subsequent left ventricular dysfunction.
    Kintsu M; Odajima S; Takeuchi K; Ichikawa Y; Todo S; Ota E; Yamauchi Y; Shiraki H; Yamashita K; Fukuda T; Hisamatsu E; Minami H; Hirata KI; Tanaka H
    J Cardiol; 2024 Aug; 84(2):119-125. PubMed ID: 37949314
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Decline in Left Ventricular Ejection Fraction Following Anthracyclines Predicts Trastuzumab Cardiotoxicity.
    Goel S; Liu J; Guo H; Barry W; Bell R; Murray B; Lynch J; Bastick P; Chantrill L; Kiely BE; Abdi E; Rutovitz J; Asghari R; Sullivan A; Harrison M; Kohonen-Corish M; Beith J
    JACC Heart Fail; 2019 Sep; 7(9):795-804. PubMed ID: 31401102
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Usefulness of cardiac magnetic resonance for early detection of cancer therapeutics-related cardiac dysfunction in breast cancer patients.
    Terui Y; Sugimura K; Ota H; Tada H; Nochioka K; Sato H; Katsuta Y; Fujiwara J; Harada-Shoji N; Sato-Tadano A; Morita Y; Sun W; Higuchi S; Tatebe S; Fukui S; Miyamichi-Yamamoto S; Suzuki H; Yaoita N; Kikuchi N; Sakota M; Miyata S; Sakata Y; Ishida T; Takase K; Yasuda S; Shimokawa H
    Int J Cardiol; 2023 Jan; 371():472-479. PubMed ID: 36115441
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Trastuzumab and Cardiac Outcomes in Breast Cancer: A Story We Know by Heart?
    Milano G; Chamorey E; Ferrero JM
    JAMA Oncol; 2016 Jan; 2(1):21-2. PubMed ID: 26540493
    [No Abstract]   [Full Text] [Related]  

  • 37. Anthracyclines induce early changes in left ventricular systolic and diastolic function: A single centre study.
    Boyd A; Stoodley P; Richards D; Hui R; Harnett P; Vo K; Marwick T; Thomas L
    PLoS One; 2017; 12(4):e0175544. PubMed ID: 28407011
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Superiority of left heart deformation in early anthracycline-related cardiac dysfunction detection.
    Giang M N; Nguyen H H; Vo DT; Ho Huynh Quang T; Phan DTH; Chau NH
    Open Heart; 2023 Nov; 10(2):. PubMed ID: 38011990
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Strain-Guided Management of Potentially Cardiotoxic Cancer Therapy.
    Thavendiranathan P; Negishi T; Somerset E; Negishi K; Penicka M; Lemieux J; Aakhus S; Miyazaki S; Shirazi M; Galderisi M; Marwick TH;
    J Am Coll Cardiol; 2021 Feb; 77(4):392-401. PubMed ID: 33220426
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Two-dimensional myocardial strain imaging detects changes in left ventricular systolic function immediately after anthracycline chemotherapy.
    Stoodley PW; Richards DA; Hui R; Boyd A; Harnett PR; Meikle SR; Clarke J; Thomas L
    Eur J Echocardiogr; 2011 Dec; 12(12):945-52. PubMed ID: 21965152
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.